OCEAN BIOMEDICAL, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.7 USD | -2.30% |
|
-2.30% | +157.58% |
| 15/04 | Ocean Biomedical, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 | CI |
| 08/03 | Ocean Biomedical, Inc. Appoints Amy Griffith as Director | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2021 | - | Sales 2022 | - | Capitalization | 11Cr 920.18Cr |
|---|---|---|---|---|---|
| Net income 2021 | -6.2Cr -517.52Cr | Net income 2022 | -1.7Cr -141.9Cr | EV / Sales 2021 | - |
| Net Debt 2021 | 0.12 9.93 | Net Debt 2022 | 1.19 99.08 | EV / Sales 2022 | - |
| P/E ratio 2021 |
-2.8
x | P/E ratio 2022 |
-10.5
x | Employees | - |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 28.01% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | -2.30% | ||
| 1 week | -2.30% | ||
| Current month | +21.43% | ||
| 1 month | -5.03% | ||
| 3 months | +213.08% | ||
| 6 months | +60.38% | ||
| Current year | +157.58% |
1 week
1.44
2.03
1 month
1.252.09
Current year
0.527.79
1 year
0.5212.08
3 years
0.5226.60
5 years
0.5226.60
10 years
0.5226.60
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +4.26% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 16/24/16 | 1.7 | -2.30% | 279,783 |
| 15/24/15 | 1.74 | +11.54% | 786,999 |
| 14/24/14 | 1.56 | +2.63% | 128,828 |
| 13/24/13 | 1.52 | -0.98% | 193,231 |
| 10/24/10 | 1.535 | -11.78% | 252,351 |
Delayed Quote Nasdaq, May 17, 2024 at 01:30 am IST
More quotes
Ocean Biomedical, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing therapeutic products in oncology, fibrosis, infectious diseases, and inflammation. The Company helps to accelerates the development and commercialization of assets from research universities and medical centers. In oncology, it is engaged in developing a mono-specific and two bi-specific humanized monoclonal antibodies (mAb), product candidates targeting Chi3l1 for the treatment of non-small cell lung cancer (NSCLC), and of glioblastoma multiforme (GBM). It offers three product candidates based on the novel target discoveries: a malaria vaccine candidate targeting either or both of PfSEA-1, and parasite antigen PfGARP, which is referred to as its ODA-570 candidate; a humanized mAb malaria therapeutic candidate targeting PfGARP, which is referred to as ODA-611 candidate, and a small molecule malaria therapeutic candidate targeting PfGARP, which is referred to as ODA-579 candidate.
| 1st Jan change | Capi. | |
|---|---|---|
| +157.58% | 6.03Cr | |
| +8.29% | 11TCr | |
| +10.21% | 11TCr | |
| +0.41% | 2.23TCr | |
| -11.90% | 2.22TCr | |
| -5.99% | 1.94TCr | |
| -37.36% | 1.79TCr | |
| -5.17% | 1.72TCr | |
| +7.70% | 1.43TCr | |
| +37.65% | 1.25TCr |
- Stock Market
- Equities
- OCEA Stock
